false 0000855683 0000855683 2026-07-24 2026-07-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 24, 2026

 

Milestone Scientific Inc.

(Exact name of registrant as specified in its charter)

 

Delaware  001-14053  13-3545623

(State or other jurisdiction 

of incorporation)

 

(Commission 

File Number)

 

(IRS Employer 

Identification No.)

 

425 Eagle Rock Road, Ste 403, 
Roseland, New Jersey 07068
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code (973) 535-2717

 

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name on exchange on which registered
Common Stock   MLSS   NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

 

 

 

 

 

 

Item 8.01 — Other Events

 

On July 24, 2026, Milestone Scientific Inc. (the “Company”) received notices of conversion (the “Conversion Notices”) from Benedetta Casamento, Dr. Didier Demesmin and Neal Goldman, each of whom is a director of the Company (collectively, the “Holders”), with respect to the Company’s amended and restated promissory notes held by the Holders (the “Convertible Bridge Notes”).

 

As previously disclosed, the Convertible Bridge Notes were originally issued in an aggregate principal amount of $800,000 and were partially converted in connection with the Company’s private placement that closed on April 20, 2026. The Conversion Notices constitute the Holders’ elections, pursuant to Section 5(a) of the Convertible Bridge Notes, to convert the remaining outstanding principal amount and accrued interest under their respective Convertible Bridge Notes into shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”). After such partial conversions, the outstanding principal amounts of the Convertible Bridge Notes covered by the Conversion Notices held by each of the Holders are as follows: $116,495.47 for Ms. Casamento; $58,247.73 for Dr. Demesmin; and $291,238.66 for Mr. Goldman.

 

Pursuant to the Conversion Notices and the Convertible Bridge Notes, the conversions will become effective automatically at such time as the Fair Value (as defined in the Convertible Bridge Notes) of the Common Stock is not less than $0.50 per share and the applicable Holder is permitted to buy and sell securities of the Company in compliance with the Company’s Insider Trading Policy. No shares of Common Stock have been issued pursuant to the Conversion Notices as of the date of this Current Report on Form 8-K.

 

Item 9.01 — Financial Statements and Exhibits

 

(d) Exhibits.

 

Exhibit No.   Description
99.1   Form of Notice of Conversion of Promissory Note
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  MILESTONE SCIENTIFIC INC.
     
Dated: July 29, 2026 By: /s/ Eric Hines
    Eric Hines
    Chief Executive Officer

 

 

 

 

Exhibit 99.1

 

Form of Notice of Conversion

of

Promissory Note

(pursuant to Section 5(a) of the Note)

 

Reference is hereby made to that certain Promissory Note of Milestone Scientific Inc. (the “Company”) dated April 8, 2025, as amended, issued to the undersigned holder in the original principal amount of [●] (the “Note”) and on April 20, 2026 partially converted into shares of the Company, issued as part of a series of promissory notes in the aggregate principal amount of $800,000. Terms used herein as defined terms and not defined herein shall have the meaning ascribed thereto in the Note.

 

The undersigned holder of the Note hereby notifies the Company of its election, pursuant to Section 5(a) of the Note, to convert the entire unpaid principal amount of and accrued interest on the Note effective, without any further or other notice to the Company, at such time as the Fair Value of the shares of Common Stock of the Company shall be not less than $0.50 per share; provided that the undersigned shall then be entitled to buy and sell securities of the Company in compliance with the Insider Trading Policy of the Company, including without limitation obtaining any necessary pre-clearance.

 

 
 Name of Holder: [●]